共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer显示文摘Androgen receptor (AR), a hormonal transcription factor, plays important roles during prostate cancer progression and is a key target for therapeutic interventions. While androgen-deprivation therapies are initially successful in regressing prostate tumors, the disease ultimately comes back as castration-resistant prostate cancer (CRPC) or at the late stage as neuroendocrine prostate cancer (NEPC). CRPC remains largely dependent on hyperactive AR signaling in the milieu of low androgen, while NEPC is negative of AR expression but positive of many AR-repressed genes. Recent technological advances in genome-wide analysis of transcription factor binding sites have revealed an unprecedented set of AR target genes. In addition to its well-known function in activating gene expression, AR is increasingly known to also act as a transcriptional repressor. Here, we review the molecular mechanisms by which AR represses gene expression. We also summarize AR-repressed genes that are aberrantly upregulated in CRPC and NEPC and represent promising targets for therapeutic intervention. | Galina Gritsina Wei-Qiang Gao Jindan Yu | 2019 | Asian Journal of Andrology2019，21，3： | 4 |
| 2 | 前列腺癌患者睾酮替代治疗的安全性研究进展显示文摘男性性腺功能减退症是由于雄激素缺乏引起的一种临床综合征,睾酮替代治疗(TRT)是其首选治疗方法.但对于既往有前列腺癌病史的患者,TRT的应用一直存在争议.近年来,文献报道了不同阶段前列腺癌患者接受TRT的安全性研究,包括癌前病变期,主动监测、根治性治疗后及进展期前列腺癌.本文回顾这些文献并对TRT在前列腺癌患者中应用的安全性研究进展进行综述. | 汪奇波 朱绍兴 | 2020 | 中国当代医药2020，27，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员